First Trust Advisors LP raised its holdings in shares of Sanofi SA (NYSE:SNY) by 4.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 547,292 shares of the company’s stock after buying an additional 20,874 shares during the period. First Trust Advisors LP’s holdings in Sanofi were worth $24,448,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in SNY. Fisher Asset Management LLC boosted its position in shares of Sanofi by 3.6% during the second quarter. Fisher Asset Management LLC now owns 15,622,562 shares of the company’s stock valued at $625,059,000 after buying an additional 549,110 shares during the period. Hamlin Capital Management LLC boosted its position in shares of Sanofi by 16.7% during the second quarter. Hamlin Capital Management LLC now owns 2,066,689 shares of the company’s stock valued at $82,688,000 after buying an additional 295,930 shares during the period. American Century Companies Inc. purchased a new position in shares of Sanofi during the second quarter valued at approximately $7,602,000. OLD Mission Capital LLC purchased a new position in shares of Sanofi during the second quarter valued at approximately $7,189,000. Finally, Aperio Group LLC boosted its position in shares of Sanofi by 18.9% during the third quarter. Aperio Group LLC now owns 960,160 shares of the company’s stock valued at $42,890,000 after buying an additional 152,734 shares during the period. Institutional investors and hedge funds own 7.53% of the company’s stock.
Shares of NYSE SNY opened at $44.78 on Tuesday. The company has a quick ratio of 0.85, a current ratio of 1.22 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $110.76 billion, a P/E ratio of 14.31, a PEG ratio of 2.50 and a beta of 0.70. Sanofi SA has a 52-week low of $37.43 and a 52-week high of $46.25.
Sanofi (NYSE:SNY) last announced its quarterly earnings results on Wednesday, October 31st. The company reported $1.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.09. The firm had revenue of $9.39 billion during the quarter, compared to analyst estimates of $9.10 billion. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. Sanofi’s quarterly revenue was up 1.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.71 earnings per share. Analysts anticipate that Sanofi SA will post 3.09 EPS for the current year.
Several research analysts have issued reports on the company. Citigroup upgraded Sanofi from a “neutral” rating to a “buy” rating in a research report on Friday, August 10th. Bank of America upgraded Sanofi from a “neutral” rating to a “buy” rating and set a $55.00 target price for the company in a research report on Monday, September 10th. Zacks Investment Research upgraded Sanofi from a “sell” rating to a “hold” rating in a research report on Tuesday, August 28th. Deutsche Bank restated a “buy” rating on shares of Sanofi in a research report on Wednesday, August 1st. Finally, BNP Paribas upgraded Sanofi from a “neutral” rating to an “outperform” rating in a research report on Wednesday, August 1st. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company’s stock. Sanofi presently has an average rating of “Hold” and an average price target of $49.00.
In related news, major shareholder Sanofi sold 104,552 shares of the business’s stock in a transaction that occurred on Thursday, September 6th. The stock was sold at an average price of $406.68, for a total value of $42,519,207.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.00% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/11/06/sanofi-sa-sny-holdings-lifted-by-first-trust-advisors-lp.html.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Further Reading: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.